PyrOjas Corporation is a biotechnology company advancing innovative solutions in cancer immunotherapy. The companys proprietary platforms, PyroTIMER and PyroCells, address key challenges in T cell therapies and personalized cancer vaccines. PyroTIMER: A universal, licensable technology designed to enhance the persistence, activation, and efficacy of CAR-T and TCR-T cell therapies by overcoming immunosuppressive tumor microenvironments. PyroCells: A personalized cancer vaccine platform leveraging whole-tumor modifications to address tumor heterogeneity, enabling scalable, point-of-care manufacturing within 24 hours. PyrOjas aims to improve treatment outcomes and expand access to effective cancer therapies through robust science, strong industry partnerships, and a focus on patient-centric innovation.
